Trial Profile
An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Melphalan (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Delcath Systems
- 30 Jun 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 10 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Jan 2019.
- 10 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2018.